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Parkinson’s disease (PD) is the second most common neurodegenerative
disease. Its pathological markers include Lewy bodies and Lewy
neuritis, which primarily affect the substantia nigra. However, in
recent years, mounting evidence suggests that PD is a multifocal
neurodegenerative process that influences several neuronal structures
aside from the substantia nigra, one of which is the enteric nervous
system. Many clinical studies have reported that patients with PD
experience gastrointestinal dysfunction for many years before
the onset of motor symptoms. Emerging evidence indicates that
α-synuclein deposition may start in the enteric nervous system and
then propagate to the central nervous system. The gut-brain axis
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plays an important role in PD pathogenesis. Recent evidence suggests
that these interactions may be primarily affected by the intestinal
microbiota. In this review, the authors discuss recent research, and
illustrate how changes in the composition of the gut microbiota
may trigger inflammation, thus contributing to neurodegeneration
in PD.

Parkinson’s disease, α-synuclein, gut microbiota,
gut-brain axis, inflammation

1

Neurodegenerative diseases

Neurodegenerative diseases are characterized by
the progressive loss of neurons in the nervous
system. The most common neurodegenerative
diseases include Alzheimer’s disease (AD),
Parkinson’s disease (PD), amyotrophic lateral
sclerosis, and Huntington’s disease, among others.
The etiology and pathogenesis of these diseases
remain largely unknown. Aging is the major risk

factor for these diseases. Aging is accompanied
by a series of cellular and functional impairments,
such as cell dysfunction, genomic and protein
instability, and impaired mitochondrial function.
Thus, age-related vulnerability to neurodegenerative disease occurs on a background of
organ functional decline.
The neurodegenerative diseases share common
pathological characteristics of aberrant protein
aggregation and deposition. Each neurode-
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generative disease is associated with the
accumulation of major and specific misfolded
proteins, such as tau and Aβ in AD, α-synuclein
in PD, and huntingtin in Huntington’s disease.
Pathological accumulation of misfolded neuronal
proteins leads to synaptic dysfunction and
neuronal death and, thus, patients experience problems with movement, abstract thinking, cognition,
emotional feelings, memory, and other abilities.

2

Gastrointestinal pathology in PD

As the second most common multisystem neurodegenerative disease, PD is associated with both
motor and non-motor symptoms. The deposition
of Lewy bodies and Lewy neurites containing
misfolded α-synuclein (α-Syn) aggregation in
neuronal perikaryal and neuronal processes, and
the selective loss of midbrain dopaminergic (DA)
neurons in the substantia nigra pars compacta
are hallmarks of PD, and eventually lead to motor
impairment including bradykinesia, tremor, and
postural instability [1, 2].
Except for the above-mentioned degenerative
changes in midbrain DA neurons, which are
responsible for motor symptoms in PD, widespread
neuropathological changes in the autonomic
nervous system, lower brainstem, cerebral cortex,
and olfactory structures are also found in individuals with PD [3–6]. It has become increasingly
evident that extranigral pathology is associated
with a broad spectrum of non-motor symptoms
in PD [7, 8]. Gastrointestinal (GI) dysfunction
is a prominent nonmotor manifestation of PD,
which usually occurs at the very early stage of
the disease, years before the appearance of motor
symptoms. GI symptoms usually include excessive
salivation, constipation, dysphagia, esophageal
motility disorder, and gastric dysfunction. Constipation is usually the first symptom of PD, and
affects up to 80% of PD patients. Furthermore,
some studies have found that patients with PD

experience constipation for more than 20 years
before the onset of motor symptoms [6, 7, 9, 10].
Furthermore, an animal study found that the A53T
α-Syn mice display significant GI dysfunction
prior to the motor impairments and CNS α-Syn
pathology [11]. According to Braak’s hypothesis,
the pathological process of PD initiates in the
enteric nervous system (ENS). Hence, α-Synassociated neurodegeneration in the ENS is a
manifestation of the onset of motor symptoms
in PD patients [4, 12]. Several neuropathological
research studies have suggested that there is
deposition of α-Syn-immunoreactive Lewy neurites
and Lewy bodies in the GI tract, even up to
20 years before the onset of PD motor symptoms
[13–15]. However, the specific relationship between
ENS and central nervous system (CNS) pathologies
remains largely unknown.

3

Innervation of the GI tract

Based on the topographic distribution of Lewy
bodies in PD patients, Braak and colleagues
hypothesized that α-Syn pathology initiates in
ENS, and then spreads to the brain. Because early
α-Syn aggregation is commonly found in structures
providing parasympathetic innervation to the
intestine in the early stages of PD, the vagal nerve
may serve as the conduit of communication
between the gut and brain [3, 5, 16].
Normal intestinal physiological processes, such
as absorption of nutrients, and induction of
mucosal and systemic immune response, are
dependent on the GI tract. Gut motility is controlled
by extrinsic input from the dorsal motor nucleus
of the vagus (DMV) and paravertebral sympathetic
ganglia, but also by local reflexes mediated by
intrinsic neurons of the ENS [17–20]. Parasympathetic output originates in the DMV of the
medulla and the sacral parasympathetic nucleus
of the spinal cord [21, 22]. Sympathetic output
originates from the prevertebral ganglia [23, 24].
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4

Gut microbiota in PD

The gut is a complicated organ and is home to
100 trillion bacteria, which outnumber the cells
of the human body by a factor of 10. The gut
microbiota includes approximately 3 million genes,
150 times greater than the human genome. More
interestingly, for most individuals, one-third of the
gut microbiota is the same among the population,
while two-thirds is special to each subject [25].
A diverse and balanced gut microbiota— and its
subsequent maintenance—plays a fundamental
role in the health status of the host. Some research
has shown that alterations in gut microbiota
composition in humans are related to PD, and
that these changes may be a risk factor for PD.
According to a study by Scheperjans, different
bacterial families of gut microbiota are closely
associated with PD motor phenotypes. Enterobacteriaceae in patients with postural balance
disorder and abnormal gait phenotype were found
to be significantly more abundant in tremorpositive patients. Furthermore, the severity of
these symptoms is positively correlated with the
concentration of Enterobacteriaceae [26]. In contrast,
another group reported that the abundance
of Enterobacteriaceae did not differ among PD
phenotypes [27]. Both teams found that bacterial
overgrowth in the small intestines of patients
with PD was related to worse motor function
[28, 29]. In addition, there is a strong correlation
between Helicobacter pylori infection in the GI tract
and the deterioration of motor function in patients
with PD [30–32]. In fact, Braak also hypothesized
that sporadic PD may be triggered by an unknown
pathogen reaching the gut, which is then transported to the brain [3].
Recently, the concept of “gut-brain axis” has
been introduced and largely accepted. In the past
few years, some research has found that the gut
microbiota has a profound impact on the CNS
[33]. In 2016, Mazmanian et al. found that gut
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microbiota promotes motor and GI dysfunction
[34]. When gut bacteria are eliminated by
antibiotics, or under germ-free conditions, α-Synoverexpressing (ASO) mice exhibited reduced
motor deficits compared with mice harboring
a complex microbiota. At the same time, they
observed much less α-Syn pathology in the substantia nigra of germ-free ASO animals compared
with control ASO mice with microbiota in the GI
tract [34]. Moreover, Michel et al. found that Pink1
knockout mice showed a significant decrease of
dopaminergic axonal varicosities in the striatum
after intestinal infection with bacteria. These mice
exhibited PD-like motor impairment which can be
alleviated by levodopa treatment [35]. Clinical
investigations have demonstrated that the microbiomes of PD patients were significantly different
from those of control subjects [26, 36, 37]. To
determine whether human gut microbes affect
PD onset and progression, researchers collected
fecal samples from patients with PD and healthy
controls, and transferred them into germ-free
animals. As a result, PD-derived gut microbiota
not only had a strong effect on the microbial
communities but also exacerbated motor dysfunction [34].

5

Inflammation and PD

As mentioned above, the correlation between
changes in the gut microbiota and PD has been
established. However, how different microbial
populations change and their physiological
outcomes remain unclear. One clinical investigation
reported that the expression of pro-inflammatory
cytokines (tumor necrosis factor-alpha, interferongamma, and interleukin-1 [IL-1] and IL-1β) were
increased in colonic biopsies obtained from PD
patients [38]. Another study measured immuneand angiogenesis-related proteins in human stool,
and found that the levels of immune factors in
PD patients were higher than controls [39].
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Nevertheless, whether changes in the gut microbiota
cause the production of pro-inflammatory cytokines
in the gut of PD patients remains elusive. Recent
studies have shown that short-chain fatty acids,
one of many gut microbiota metabolites, promote microglia to fully mature and le ad to an
inflammatory response [40]. Similar results were
observed by Sarkis and colleagues in animal
models [34]. Moreover, other groups have found
that microglia activation and neuroinflammation
alter neuronal function and increase cell death
in PD models [41, 42]. Recently, another clinical
investigation found that patients with inflammatory
bowel disease (IBD) had a higher risk of PD
when compared with non-IBD individuals [43].
All these results indicate that GI inflammation
plays an important role in the development of
PD pathology.
Inflammation has long been speculated to be a
key contributor to the pathogenesis of PD. In one
study, pro-inflammatory lipopolysaccharides (LPS)
were reported to initiate the degeneration of DA
neurons in the substantia nigra of rodents [44–46].
Moreover, environmental factors, such as the
pesticide rotenone, in combination with LPS,
worked synergistically to induce the selective
degeneration of DA neurons [47]. These results
provided evidence that inflammation is an important mediator in the pathogenesis of PD.
Inflammation, however, is a “double-edged
sword” in PD. Inflammation is the first line of
defense against infections and injuries. However,
an excessive inflammatory response is harmful
to host cells [48]. α-Syn is known to aggregate in
an inflammatory environment, which activates
microglia [49]. The over-activated microglia cause
damage to neurons [41, 50]. Due to the inability
of neurons to divide and recover from damage,
neurons are highly vulnerable to auto-destructive
immune and inflammatory processes [51–53]. This
physiological property may prevent neurons
from recovering neurological function at sites of

inflammation and even exacerbate neuronal
damage.

6 Transmission of pathological α-Syn from
the gut to the brain
Misfolded protein aggregates are key pathological
hallmarks of neurodegenerative disorders. Protein
aggregation occurs through “nucleation seed”
polymerization model, and is not a random process
[54, 55]. Stable “seeds” are formed in the nucleation
phase. One widely accepted view is that the seeds
play an important role in the initiation and
development of disease [56]. These seeds can
recruit and convert the normal protein, generating
aggregated oligomers, which in turn results in the
formation and propagation of amyloid fibrils [57].
The fibrils are not only a key pathological
characteristic of neurodegeneration, but also the
reason for neurodegeneration. In the early stages
of neurodegeneration, pathological changes, such
as aggregated fibrils of misfolded proteins and
neurological disorder, are localized in a confined
area of the nervous system. However, in later
stages, such changes become more prevalent and
dispersed, indicating that pathological fibrils
spread throughout the nervous system. Mounting
evidence indicates that misfolded fibrillar forms
of α-Syn self-propagate and spread among
interconnected regions of the CNS, suggesting that
cell-to-cell transmission of pathological proteins
may explain disease progression [58–63]. Recently,
it has been proposed that pathological misfolded
proteins spread between neurons in a prion-like
manner within the nervous system [64]. The
concept of the prion was first proposed by S.B.
Prusiner, who purified the scrapie agent, and found
that is a protein with the capability of replicating
without nucleic acid. The prion diseases are caused
by the conformational change of normal cellular
protein into an abnormal form, termed “prions”,
which then serve as templates, further induce the

https://mc03.manuscriptcentral.com/brainsa

| Brain Science Advances

Brain Sci. Adv.

misfolding of normal proteins. It is now believed
that this induced conformational self-propagation
plays a major role in many neurodegenerative
diseases, including PD and AD [65, 66].
The misfolded α-Syn fibrils can induce monomeric α-Syn to misfold in the same cell. The
α-Syn then aggregates and is released into the
extracellular space. The aggregates can enter a
new cell, the misfolded α-Syn fibrils further seed
soluble α-Syn into a misfolded and aggregated
form. Thus, the misfolded protein can act as a
template for inducing monomeric α-Syn to misfold
and spread disease from one cell to another
[67–70]. Recently, researchers have provided direct
evidence of gut-brain α-Syn transmission in rodent
models. Li and colleagues found that pathological
α-Syn fibrils derived from PD patients migrate
from the GI tract to the brain through the vagus
nerve in a rat model. At the same time, they even
observed similar phenomena when injecting
preformed artificial oligomeric and fibrillar α-Syn
into the GI tract [71]. In a parallel study, the
authors injected α-Syn performed fibrils into the
duodenal and pyloric muscular layer of mice,
and found that aggregates of pathological α-Syn
can spread from the gut to the brain through the
vagus nerve. What’s more, the α-Syn pathology
was accompanied by loss of dopaminergic neurons
and was also associated with PD-like motor and
non-motor symptoms [72]. Another study led by
Nathalie Van Den Berge found that pathological
α-Syn can spread along both the sympathetic and
parasympathetic pathways in transgenic rats
that overexpressed a human form of α-Syn [73].
All these new rodent models provide useful
tools to explore the specific relationship between
the gut-brain axis and PD pathology.

7

77

of gut microbes is important for maintaining
the health of the brain and gut. Changes in gut
microorganisms affect the development and
function of the CNS through the gut-brain axis;
the hypothesis is illustrated in Fig. 1. Thus, it is
important to study the relationship between the
human gut microbiome and its functions in health
and diseases. Based on current evidence, we
propose that altered microbiota in the gut promotes the aberrant aggregation of α-Syn by
enhancing inflammation. The aggregated α-Syn
fibrils further self-aggregate and spread to the CNS
through the gut-brain axis. A better understanding
of gut-brain interactions in PD may provide new
insights into early diagnosis and lead to novel
therapeutic methods.

Conclusions

Dysbiosis in the GI tract may be a cause of PD
and other neurodegenerative diseases. The balance
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Fig. 1 Gut microorganisms affect the function of the central
nervous system through the gut-brain axis.
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